A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis 1
dc.contributor.author | Patterson, David | en_US |
dc.contributor.author | Abell, Thomas L. | en_US |
dc.contributor.author | Rothstein, Robin | en_US |
dc.contributor.author | Koch, Kenneth | en_US |
dc.contributor.author | Barnett, Jeffrey | en_US |
dc.date.accessioned | 2010-06-01T21:29:29Z | |
dc.date.available | 2010-06-01T21:29:29Z | |
dc.date.issued | 1999-05 | en_US |
dc.identifier.citation | Patterson, David; Abell, Thomas; Rothstein, Robin; Koch, Kenneth; Barnett, Jeffrey (1999). "A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis 1 ." The American Journal of Gastroenterology 94(5): 1230-1234. <http://hdl.handle.net/2027.42/74548> | en_US |
dc.identifier.issn | 0002-9270 | en_US |
dc.identifier.issn | 1572-0241 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74548 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10235199&dopt=citation | en_US |
dc.description.abstract | A double-blind, multicenter, randomized trial was conducted to compare the side effects and efficacy of domperidone and metoclopramide in symptomatic diabetic gastroparesis. Methods : Ninety-three insulin-dependent diabetes patients with a ≥ 3-month history of gastroparesis symptoms were recruited; 48 received domperidone 2 × 10-mg tablets 4 times daily, and 45 received metoclopramide 1 × 10-mg tablet + 1 placebo tablet 4 times daily. Nausea, vomiting, bloating/distension, and early satiety were evaluated for severity after 2 and 4 wk. Adverse central nervous system (CNS) effects of somnolence, akathisia, asthenia, anxiety, depression, and reduced mental acuity were elicited and graded for severity at 2 and 4 wk. Results : Domperidone and metoclopramide were equally effective in alleviating symptoms of diabetic gastroparesis. Elicited adverse CNS effects were more severe and more common with metoclopramide. Somnolence was acknowledged by 49% of patients (mean severity score, 1.03) after 4 wk of metoclopramide compared with 29% of patients (mean severity score, 0.49) after 4 wk of domperidone (incidence, p = 0.02 ; severity; p = 0.03 ). A reduction in mental acuity was acknowledged by 33% of patients (mean severity score, 0.62) after 4 wk of metoclopramide, compared with 20% of patients (mean severity score, 0.27) after 4 wk of domperidone (incidence, p = 0.04 ; severity, p = 0.04 ). Akathisia, asthenia, anxiety, and depression were also acknowledged less often, and at a lower severity, after 4 wk of domperidone, although these differences were not statistically significant. Conclusions : Domperidone and metoclopramide effectively reduce the symptoms of diabetic gastroparesis; CNS side effects are more pronounced with metoclopramide. | en_US |
dc.format.extent | 299684 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/octet-stream | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 1999 by Am. Coll. of Gastroenterology | en_US |
dc.title | A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis 1 | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, Michigan USA | en_US |
dc.contributor.affiliationother | Virginia Mason Clinic Hospital, Seattle, Washington, USA | en_US |
dc.contributor.affiliationother | University of Tennessee Medical Center, Memphis, Tennessee, USA | en_US |
dc.contributor.affiliationother | Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA | en_US |
dc.contributor.affiliationother | Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA | en_US |
dc.identifier.pmid | 10235199 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74548/1/j.1572-0241.1999.00456.x.pdf | |
dc.identifier.doi | 10.1111/j.1572-0241.1999.00456.x | en_US |
dc.identifier.source | The American Journal of Gastroenterology | en_US |
dc.identifier.citedreference | Feldman M., Schiller L.R.. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med 1983; 98: 378 – 384. | en_US |
dc.identifier.citedreference | Keshavarzian A., Iber F.L.. Gastrointestinal involvement in insulin-requiring diabetes mellitus. J Clin Gastroenterol 1987; 9: 685 – 692. | en_US |
dc.identifier.citedreference | Van Dijl P.W., Hoffman S.J., Van Doormaal J.J., et al. Low prevalence of symptomatic gastric and esophageal motor dysfunction in diabetes mellitus. Gastroenterology 1989; 96: A524. | en_US |
dc.identifier.citedreference | Reynolds J.C.. Prokinetic agents: A key in the future of gastroenterology. Gastroenterol Clinics North Am 1989; 18: 437 – 457. | en_US |
dc.identifier.citedreference | Kassander P.. Asymptomatic gastric retention in diabetics (gastroparesis diabetoricum). Ann Int Med 1958; 48: 797 – 812. | en_US |
dc.identifier.citedreference | Horowitz M., Harding P.E., Maddox A.F., et al. Gastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 151 – 159. | en_US |
dc.identifier.citedreference | von der Ohe M., Camilleri M., Zimmerman B.R.. Management of diabetic enteropathy. The Endocrinologist 1993; 3: 400 – 408. | en_US |
dc.identifier.citedreference | Drenth J.P.H., Engels L.G.J.B.. Diabetic gastroparesis. A critical reappraisal of new treatment strategies. Drugs 1992; 44: 537 – 553. | en_US |
dc.identifier.citedreference | Albibi R., McCallum R.W.. Metoclopramide: Pharmacology and clinical application. Ann Intern Med 1983; 98: 86 – 95. | en_US |
dc.identifier.citedreference | Van Outryve M., De Nutte N., Van Eghem P., et al. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: A double-blind, placebo-controlled study. Scand J Gastroenterol 1993; 28 ( suppl 195 ): 47 – 53. | en_US |
dc.identifier.citedreference | Champion M.C., Gulenchyn K., O'Leary T., et al. Domperidone (Motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis. Am J Gastroenterol 1987; 82: 975. | en_US |
dc.identifier.citedreference | Heer M., Muller-Duysing W., Benes I., et al. Diabetic gastroparesis: Treatment with domperidone—A double-blind, placebo-controlled trial. Digestion 1983; 27: 214 – 217. | en_US |
dc.identifier.citedreference | Horowitz M., Harding P.E., Chatterton B.E., et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 1 – 9. | en_US |
dc.identifier.citedreference | Koch K.L., Stern R.M., Stewart W.R., et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term domperidone treatment. Am J Gastroenterol 1989; 84: 1069 – 1075. | en_US |
dc.identifier.citedreference | Kozarek R.. Domperidone for symptomatic management of diabetic gastroparesis in metoclopramide treatment failures. Adv Ther 1990; 7: 61 – 68. | en_US |
dc.identifier.citedreference | McCallum R.W. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol 1985; 80: 1008 – 1016. | en_US |
dc.identifier.citedreference | Parkes J.D.. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986; 9: 517 – 531. | en_US |
dc.identifier.citedreference | Ahn Y.H., Maturu P., Steinheber F.U., Goldman J.M.. Association of diabetes mellitus with gastric bezoar formation. Arch Intern Med 1987; 147: 527 – 528. | en_US |
dc.identifier.citedreference | Maddern G.J., Kiroff G.K., Leppard P.I., et al. Domperidone, metoclopramide, and placebo. J Clin Gastroenterol 1986; 8: 135 – 140. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.